Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Potential Weak Interaction

Elbasvir/Grazoprevir

Ruxolitinib

Summary:

Coadministration has not been studied. Elbasvir/grazoprevir are substrates of CYP3A4 and P-gp and are weak inhibitors of CYP3A4. Ruxolitinib may inhibit P-gp in the intestine which may increase systemic exposure of elbasvir/grazoprevir. This is unlikely to be clinically relevant due to the large therapeutic safety margins of elbasavir/grazoprevir. Ruxolitinib is metabolized by CYP3A4 (major) and CYP2D9 (minor). Coadministration with the moderate CYP3A4 inhibitor erythromycin increased ruxolitinib Cmax and AUC by 8% and 27%, respectively. Elbasvir/grazoprevir is expected to have a smaller effect on ruxolitinib exposure therefore no dose adjustment is required.

Description:

(See Summary)

View all available interactions with Elbasvir/Grazoprevir by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2025 The University of Liverpool. All rights reserved.